222 related articles for article (PubMed ID: 22166636)
1. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
Li ZC; Li HJ; Dai LL; Gao YQ; Cai WP; Li HY; Huang XJ; Zhang T; Wu H
Chin Med J (Engl); 2010 Dec; 123(24):3587-90. PubMed ID: 22166636
[TBL] [Abstract][Full Text] [Related]
2. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
Mankhatitham W; Lueangniyomkul A; Manosuthi W
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
[TBL] [Abstract][Full Text] [Related]
5. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
Manfredi R; Calza L; Chiodo F
HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
[TBL] [Abstract][Full Text] [Related]
6. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
[TBL] [Abstract][Full Text] [Related]
8. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
Van Welzen B; Mudrikova T; Arends J; Hoepelman A
HIV Med; 2012 Aug; 13(7):448-52. PubMed ID: 22413955
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
10. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
[TBL] [Abstract][Full Text] [Related]
12. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
McKoy JM; Bennett CL; Scheetz MH; Differding V; Chandler KL; Scarsi KK; Yarnold PR; Sutton S; Palella F; Johnson S; Obadina E; Raisch DW; Parada JP
Drug Saf; 2009; 32(2):147-58. PubMed ID: 19236121
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Kontorinis N; Dieterich DT
Semin Liver Dis; 2003 May; 23(2):173-82. PubMed ID: 12800070
[TBL] [Abstract][Full Text] [Related]
15. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
Crane HM; Van Rompaey SE; Kitahata MM
AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
[TBL] [Abstract][Full Text] [Related]
16. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
[TBL] [Abstract][Full Text] [Related]
17. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
Macías J; Castellano V; Merchante N; Palacios RB; Mira JA; Sáez C; García-García JA; Lozano F; Gómez-Mateos JM; Pineda JA
AIDS; 2004 Mar; 18(5):767-74. PubMed ID: 15075511
[TBL] [Abstract][Full Text] [Related]
18. The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection.
Wu L; Jin C; Bai S; Davies H; Rao H; Liang Y; Wu N
J Res Med Sci; 2015 Feb; 20(2):127-32. PubMed ID: 25983763
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
